http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Vi Capsular Polysaccharide Vaccine 접종 후 Vi 간접형광항체법으로 측정한 항체가의 변화
안광진 ( An Gwang Jin ),김준명 ( Kim Jun Myeong ),김응 ( Kim Eung ),정경섭 ( Jeong Gyeong Seob ),홍천수 ( Hong Cheon Su ) 대한내과학회 1990 대한내과학회지 Vol.38 No.6
N/A The efficacy of purified Vi capsular polysaccharide(CPS) vaccine against typhoid fever has recently been reported in Nepal and South Africa. These results showed approximately 75% protective efficacy, which is at least comparable or superior to other parenteral and oral vaccines. In order to evaluate the immunogenecity of the Vi-CPS typhoid vaccine manufactured at the Merieux Institute in France, we vaccinated healthy young college student volunteers with Vi-CPS, and observed the serial changes of antibody titers for 12 months using the Vi indirect fluorescence antibody test. We observed overall seroconversion in 48.1% of the volunteers, which is lower than other reports, but we found that those with relatively low pre-immunization Vi antibody titers (≤1 : 8) showed 91.7% seroconversion, while those with high pre-immunization titers (≥1 : 16) showed only 13.3% seroconvesion. Booster Vi-CPS vaccine was injected in the nonseroconversion group during a period four months after the first vaccination and followed the Vi antibody titers. The changes of Vi antibody titers were not significant. Moreover, we found that the mean Vi antibody titers between the seroconversion group and the nonseroconversion group were essentially identical from the 30th day after vaccination, with no significant decrease for up to 12 months. Also the adverse effects of the Vi CPS vaccine were negligible compared with other vaccines that are currently available. In conclusion, even though the overall seroconversion rate was lower than previous reports, there was a significant difference in the intensity of the immunogenecity according to pre-immunization Vi antibody titers, and ultimately the antibody titers in both groups became identical showing a sustained plateau for up to 12 months. In order to determine whether the protective efficacy at this acquired level of Vi antibody titers through Vi-CPS vaccination is satisfactory or not, further clinical and epidemiological studies need to be performed.